Genzyme Surgical Is Out Of General's Shadow Following January Run-up
This article was originally published in The Gray Sheet
Executive Summary
Wall Street began to take note in January of Genzyme Surgical Products' leading position in the minimally invasive cardiac surgery market, as the stock price of the Genzyme General spin-off jumped 74.2%. The issue closed the month at 10-1/8, up 5-3/16.